Tosk, Inc.

15 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Feb 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 23, 2026
The maintenance fee for Doxorubicin adjuvants to reduce toxicity and methods for using the same (US 9,061,038) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
1 fee due Oct 2, 2027
The maintenance fee for Modulators of RAS GTPase (US 11,945,803) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,468,613	Doxorubicin adjuvants to reduce toxicity and methods for using the same In force Ends no later than Feb 11, 2029 · From the USPTO record	In force	Ends no later than Feb 11, 2029	From the USPTO record
US RE48,253	Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same In force Term ends Mar 5, 2029 · Low confidence	In force	Term ends Mar 5, 2029	Low confidence
US 9,061,038	Doxorubicin adjuvants to reduce toxicity and methods for using the same In force Term ends Mar 7, 2030 · From the USPTO record	In force	Term ends Mar 7, 2030	From the USPTO record
US 8,227,517	Doxorubicin adjuvants to reduce toxicity and methods for using the same In force Term ends May 24, 2030 · From the USPTO record	In force	Term ends May 24, 2030	From the USPTO record
US 10,660,318	Non-mammalian RAS transgenic animal model In force Term ends Aug 19, 2034 · From the USPTO record	In force	Term ends Aug 19, 2034	From the USPTO record
US 12,486,255	Modulators of RAS GTPase In force Term ends Aug 6, 2039 · From the USPTO record	In force	Term ends Aug 6, 2039	From the USPTO record
US 11,945,803	Modulators of RAS GTPase In force Term ends May 28, 2040 · From the USPTO record	In force	Term ends May 28, 2040	From the USPTO record
US 11,446,303	Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions In force Term ends Jun 17, 2040 · From the USPTO record	In force	Term ends Jun 17, 2040	From the USPTO record
US 12,667,571	Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions In force Ends no later than Jun 17, 2040 · Low confidence	In force	Ends no later than Jun 17, 2040	Low confidence
US 12,109,222	Methods and Compositions for Treating Mucositis In force Ends no later than Jun 16, 2041 · Low confidence	In force	Ends no later than Jun 16, 2041	Low confidence

10 of 15 patents shown.

Pro members see all 15.

Pro members: see all 15 patents

Also on record, not counted in the 15: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 3 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 6 no status recorded

List them